Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Amryt Pharma Plc (AMYT.LN)

Amryt Pharma Plc (AMYT.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Amryt Pharma Plc 196 High Road Dept 920A, Wood Green London N22 8HH GBR

www.amrytpharma.com P: 203-026-7257

Description:

Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).

Key Statistics

Overview:

Market Capitalization, $K 457,335
Shares Outstanding, K 319,657
Annual Sales, $ 222,543 K
Annual Net Income, $ 1,000 K
Last Quarter Sales, $ 61,126 K
Last Quarter Net Income, $ -20,795 K
% of Insider Shareholders 41.21%
% of Institutional Shareholders 7.04%

Growth:

1-Year Return -26.67%
3-Year Return 61.58%
5-Year Return 38.16%
5-Year Revenue Growth 174.77%

Per-Share Information:

Most Recent Earnings -0.07 on 11/03/21
Latest Earnings Date N/A
Earnings Per Share ttm -0.49
Dividend Payout Ratio 0.00%
Most Recent Split 1-6 on 07/11/19

AMYT.LN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward 25.51
Return-on-Equity % -0.25%
Return-on-Assets % -0.10%
Profit Margin % 0.45%
Debt/Equity 0.56
Price/Sales 1.83
Price/Book 2.03
Book Value/Share 0.70
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar